Compare Aecom (ACM) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Quest Diagnostics Inc — how do they compare? Aecom trades at $62.18 (market cap $8.62B), while Quest Diagnostics Inc trades at $238.15 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 3× Aecom's market cap, and Aecom pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| ACM | DGX | |
|---|---|---|
Market Cap | $8.62B | $26.21B |
Sector | Industrials | Health |
52-Week High | $134.35 | $238.50 |
52-Week Low | $66.86 | $173.49 |
Enterprise Value | $10.81B | $31.97B |
Dividend Yield | 1.77% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock is trading at $73.30, down 3.35% in the last session, reflecting negative momentum after a Q2 2026 earnings miss. The technical outlook is bearish, with support at $72 and resistance at $76. Fundamentally, revenue reached $16.14 billion in 2025, but net income margin is thin at 1.87%, and ROE is negative. Recent news includes a securities investigation announcement and a large project charge impacting earnings.
The investment outlook is mixed: analyst consensus is bullish with a $88.25 price target, but risks include earnings volatility, a fraud probe, and rising debt-to-asset ratio. Opportunities lie in record backlog growth and new project wins like the Lisbon airport design. Investors should weigh strong institutional support against operational and legal headwinds.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
